Material Insights · Understanding the Material World

CAR-T cell therapy

A patient's own immune cells are engineered to find and kill their cancer.

Health and medicine · Biotechnology · No. 433

  • Networked and AI age
  • Readiness 9 of 9
  • Process
Health and medicine · Technology

A living drug: a patient's own immune cells are reprogrammed to hunt their cancer, then multiplied and returned in one infusion.

Chart: Illustration: CAR-T cell therapy

Where it comes from

Chart: Map of where it comes from

Immunologists in 1989 gave T cells receptors with antibody-type targeting. At Penn the approach was first tested in patients with chronic lymphocytic leukaemia in 2010, and Kymriah was approved in 2017.

Three things to know
  1. The idea of joining an antibody's targeting part to a T-cell receptor was first reported in 1989.
  2. Kymriah, approved in August 2017, was the first therapy based on gene transfer approved by the US regulator.
  3. Seven CAR-T therapies were approved in the United States by 2025, all for blood cancers such as leukaemia, lymphoma and myeloma.
The journey
  1. 1 CollectionBlood is drawn and the T cells are separated out
  2. 2 EngineeringIn a manufacturer's laboratory the cells are given a gene for a chimeric antigen receptor
  3. 3 GrowthThe changed cells are multiplied to hundreds of millions
  4. 4 InfusionThey go back into the patient in a single infusion
  5. 5 AttackThe cells find cancer cells carrying the target marker and kill them
Go deeper pick a tab to open it in full